He also pointed out that competition in the drug market had dissipated, thanks to sluggish approval prices and an overbearing regulatory system.   " We’re gonna be lowering taxes big league, we’re going to be getting rid of regulations that are unnecessary big league," he said. Trump met in the Oval Office with officials from Amgen, Johnson  Johnson, Merck, Celgene, Eli Lilly, and Novartis. 